



Leadership isn't given. It's earned.

Prozac has appeared in more than 7,500 clinical publications and is currently approved in over 85 countries. Its record of clinical use stands at more than 10 million patients worldwide.

As the world's leading prescription brand for depression, Prozac has the safety and efficacy you can trust.

PROZAC
Fluoxetine Hydrochloride

The World's Most Prescribed Antidepressant

'PROZAC' ABBREVIATED PRESCRIBING INFORMATION (FLUOXETINE HYDROCHLORIDE)

Presentation Capsules containing 20mg or 60mg fluoxetine, as the hydrochloride. Liquid containing 20mg fluoxetine, as the hydrochloride, per 5ml syrup. **Uses** **DEPRESSION: TREATMENT OF THE SYMPTOMS OF DEPRESSIVE ILLNESS, WITH OR WITHOUT ASSOCIATED ANXIETY SYMPTOMS.** *Obsessive-compulsive disorder. Bulimia nervosa:* For the reduction of binge eating and purging activity. **Dosage and Administration** (For full information, see data sheet.) For oral administration to adults only. *Depression, with or without associated anxiety symptoms - adults and the elderly:* A dose of 20mg/day is recommended. *Obsessive-compulsive disorder:* 20mg/day to 60mg/day. A dose of 20mg/day is recommended as the initial dose. *Bulimia - adults and the elderly:* A dose of 60mg/day is recommended. Because of the long elimination half-lives of the parent drug (1-3 days after acute administration; may be prolonged to 4-6 days after chronic administration) and its major metabolite (average 9.3 days), active drug substance will persist in the body for several weeks after dosing is stopped. The capsule and liquid dosage forms are bioequivalent. *Children:* Not recommended. *Patients with renal and/or hepatic dysfunction:* See 'Contra-indications' and 'Precautions' sections. **Contra-indications** Hypersensitivity to fluoxetine. Prozac should not be administered to patients with severe renal failure (GFR <10ml/min). *Usage in nursing mothers:* Prozac should not be prescribed to nursing mothers. *Monoamine oxidase inhibitors:* At least 14 days should elapse between discontinuation of an MAOI and initiation of treatment with Prozac.

At least five weeks should elapse between discontinuation of Prozac and initiation of therapy with an MAOI. Serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability and mental status changes that include extreme agitation, progressing to delirium and coma) have been reported with concomitant use or when fluoxetine had been recently discontinued and an MAOI started. Some cases presented with features resembling neuroleptic malignant syndrome. **Warnings** *Rash and allergic reactions:* Angioneurotic oedema, urticaria and other allergic reactions have been reported. Upon appearance of rash, or of other allergic phenomena for which an alternative aetiology cannot be identified, Prozac should be discontinued. **Pregnancy:** Use of Prozac should be avoided unless there is no safer alternative. **Precautions** Prozac should be discontinued in any patient who develops seizures. Prozac should be avoided in patients with unstable epilepsy; patients with controlled epilepsy should be carefully monitored. There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment. A lower dose of Prozac, eg. alternate day dosing, is recommended in patients with significant hepatic dysfunction or mild to moderate renal failure (GFR 10-50ml/min). Caution is advisable when Prozac is used in patients with acute cardiac disease. Prozac may cause weight loss which may be undesirable in underweight depressed patients. In diabetics, fluoxetine may alter glycaemic control. There have been reports of abnormal bleeding in several patients, but causal relationship to fluoxetine and clinical importance are unclear. **Drug interactions:** Increased (with lithium toxicity) or decreased lithium levels have been


reported. Lithium levels should be monitored. Because fluoxetine's metabolism involves the hepatic cytochrome P450D6 isoenzyme system, concomitant therapy with other drugs also metabolised by this system, and which have a narrow therapeutic index (eg. carbamazepine, tricyclic antidepressants), should be initiated at or adjusted to the low end of their dose range. Greater than 2-fold increases of previously stable plasma levels of cyclic antidepressants have been observed when Prozac has been administered in combination. Agitation, restlessness and gastro-intestinal symptoms have been reported in a small number of patients receiving fluoxetine in combination with tryptophan. Patients on stable phenytoin doses have developed elevated plasma concentrations and clinical phenytoin toxicity after starting fluoxetine. *For further information, see data sheet.* **Adverse Effects** Asthenia, fever, nausea, diarrhoea, dry mouth, appetite loss, dyspepsia, vomiting, rarely abnormal LFTs, headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, decreased libido, seizures, hypomania or mania, dyskinesia, movement disorders, neuroleptic malignant syndrome-like events, pharyngitis, dyspnoea, pulmonary events (including inflammatory processes and/or fibrosis), rash, urticaria, vasculitis, excessive sweating, arthralgia, myalgia, serum sickness, anaphylactoid reactions, hair loss, sexual dysfunction. The following have been reported in association with fluoxetine but no causal relationship has been established: aplastic anaemia, cerebral vascular accident, confusion, ecchymoses, eosinophilic pneumonia, gastro-intestinal haemorrhage, hyperprolactinaemia, immune-related haemolytic anaemia, pancreatitis,

pancytopenia, suicidal ideation, thrombocytopenia, vaginal bleeding after drug withdrawal. **Hyponatraemia** (including serum sodium rarely reported. This appears to be reversible. **Overdose** On the evidence available, fluoxetine overdoses, reports of acute overdosage of fluoxetine alone, have been extremely rare. One patient who reportedly took 3000mg of fluoxetine experienced 2 grand mal seizures that remitted spontaneously. **Legal Category** POM **Product Licence Numbers** 0006/0195 0006/0198 0006/0272 **Basic NHS Cost** £20.77 per pack of 30 capsules (20mg), £67.85 per pack of 98 capsules (20mg), £62.31 per pack of 30 capsules (60mg), £89.50 per 70ml bottle. **Date of Preparation or Last Review** October 1996. **Full Prescribing Information is Available from** Dista Products Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire, RG24 0AP. Telephone: Basingstoke (01256) 52011. 'PROZAC' is a Dista trade mark. **Date of preparation:** November 1996

References: 1. Data on file, Dista Products Ltd.



New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in U.S.A., Canada, and Mexico by:



SOMATICS, INC.
910 Sherwood Drive # 17
Lake Bluff IL 60044 U.S.A.

Fax: (847) 234-6763
Tel: (847) 234-6761

Selected Distributors

Distributed in the U.K. by: DANTEC Electronics, Ltd.
Garonor Way
Royal Portbury
Bristol BS20 9XE
TEL (44) 1275-375333
FAX (44) 1275-375336

Distributed in New Zealand by: WATSON VICTOR, Ltd.
4 Adelaide Rd.
Wellington, New Zealand
TEL (64) 4-385-7699
FAX (64) 4-384-4651

Distributed in India by: DIAGNO.SYS
New Delhi
TEL (91) 11-644-0546
FAX (91) 11-622-9229

Distributed in South Africa by: DELTA SURGICAL
Craighall
TEL (27) 11-792-6120
FAX (27) 11-792-6926

Distributed in Australia by: MEECO Holdings Pty. Ltd.
10 Seville St.
North Parramatta NSW 2151
Australia
TEL (61) 2630-7755
FAX (61) 2630-7365

Distributed in Scandinavia by: MEDICAL EQUIPMENT APS
Bygaden 51A
P.O. Box 23
DK-4040
Jyllinge, Denmark
TEL (45) 4-6788746
FAX (45) 4-6788748

Distributed in Pakistan by: IQBAL & CO.
Islamabad
TEL (92) 51-291078
FAX (92) 51-281623

Distributed in Israel by: BEPEX, LTD.
16, Galgalei Haplada St.
Herzliya 46722
TEL (972) 9-959586211
FAX (972) 9-9547244

CHILD AND ADOLESCENT PSYCHIATRY BOOKS FROM GASKELL

Available from good bookshops and from the Publications Department, Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146)



Unwillingly to School

Fourth edition

Edited by Ian Berg and Jean Nursten

This book describes the epidemiological aspects of school absence and offers practical help to those who are faced with helping children who fail to attend school. A multidisciplinary approach to truancy and school refusal is put forward, drawing on experience from the UK, the United States, Sweden and New Zealand. The clinical features of the various underlying conditions are also demonstrated, and the future prospects of those who display this problem outlined. This new edition of a well respected book has been comprehensively rewritten to take into account current research and thinking.

£20.00, 336pp., 1996, ISBN 0 902241 89 3

Safeguards for Young Minds

Young People and Protective Legislation

Richard White, Richard Williams, Anthony Harbour
and William Bingley

This co-publication with the NHS Health Advisory Service is concerned with aspects of the law as it applies to the welfare and protection of minors, and the management of children and adolescents in mental health services. It includes a complete update of the *Concise Guide to the Children Act 1989*, with a concise summary of the provisions of the Children Act. Particular issues relating to the use of the Mental Health Act 1983 with younger people and recent developments wrought by case law are also covered.

£10.00, 84pp., 1996, ISBN 0 902241 94 X